Brain tumor classification using a novel H1 HRMAS MRS method and robust algorithmic classifiers

D. Mintzopoulos1,2, O. C. Andronesi1,2, K. D. Blekas3, L. G. Astrakas1,4, P. M. Black7, and A. A. Tzikas1,2
1NMR Surgical Laboratory, MGH & Shriners Hospitals, Harvard Medical School, Boston, MA, United States, 2Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Boston, MA, United States, 3Computer Science, University of Ioannina, Ioannina, Greece, 4Medical Physics, University of Ioannina, Ioannina, Greece, 5Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States

Introduction— We present results combining a novel 2D TOBSY (TOtal Through-Bond SpectroscopY) 1H HRMAS MRS [1] with a robust SVM (Support Vector Machine) classifier with several feature-selection schemes [2]. Our results provide the framework for a non-subjective diagnostic approach that relies on highly informative biomarkers. This is justified because tumor classification according to histological features of the assumed cell of origin [3] is frequently controversial, since tumors often do not follow classic histology, and pathological diagnosis can therefore be subjective [4].

Materials and Methods— ♦ We analyzed fifty-five biopsies, N=9 control from epileptic surgeries and N=46 from patients with brain tumors. Tumor biopsies belonged to three categories: high-grade (N=20: 12 glioblastoma multiforme (GBM); 8 anaplastic astrocytoma (AA)); low-grade (N=17: 7 meningioma; 7 schwannoma; 3 pylocytic astrocytoma), and brain metastases (N=9: 5 from adenocarcinoma; 4 from breast cancer). Subject age ranged from 17 to 54 years. ♦ We performed ex vivo MRS employing 2D TOBSY 1H HRMAS [1]. All MRS measurements were performed on a Bruker Bio-Spin Avance NMR spectrometer (600.13 MHz) using a 4mm triple resonance (1H, 13C, 1H) HRMAS probe (Bruker), at -8°C to minimize tissue degradation. An external standard (TSP, M) =172, δ=0.00 ppm) served as reference for resonance chemical shift and for quantification. Typical parameters were, 2s repetition time, 45 ms mixing time, and 45 min total acquisition time. ♦ We quantified brain metabolites using the ratio of the cross peak volumes of the metabolites CPV(M) to the TSP diagonal peak volume DPV(TSP). This ratio normalized to the biopsy weight (w) yielded the normalized metabolite intensity I(M), I(M)=Iw/CPV(M)/DPV(TSP). ♦ A linear Support Vector Machine (SVM) [5] was employed and tried with three MRS feature selection schemes: (i) the full feature space comprised of all 16 MRS features, (ii) a reduced feature space comprised of 4 specific features [choline (Cho), lactate (Lac), lipids (Lip), and N-acetyl aspartate (NAA)], and (iii) features selected with the minimum redundancy/maximun relevance (MRMR) feature selection method [6] that captures class characteristics in a broader spectrum by reducing mutual redundancy within the feature set. We employed a standard leave-one-out training/testing scheme. Performance was evaluated using “accuracy” (the percentage of correctly classified cases), “sensitivity” (the ratio of true positives to the sum of true positives and false negatives), and “specificity” (the ratio of true negatives to the sum of false positives and true negatives).

Results— All 16 metabolites were assigned from 2D TOBSY spectra (representative spectra shown in Figure 1) according to Tugnoli V et al [7]. Saturated Lip and polyunsaturated fatty acids (PUFAs) were prominent in high-grade tumors (i.e., GBM) and metastases, but not in low-grade tumors such as the Pilocytic Astrocytomas (Figure 1). The rest of the metabolites are detected at various levels in all tumors. The performance of the linear SVM classifier is summarized in Figure 2.

Discussion— Our novel and sensitive TOBSY 1H HRMAS MRS allowed optimal identification of biomarkers and molecular and/or metabolic assessment of brain tumor biopsies —2 mg. TOBSY MRS was performed at a low temperature (8°C), maintaining tissue integrity thus allowing us to subsequently run histopathological, genomic, and/or proteomic analyses to construct molecular cancer signatures. We reliably detected at least 16 metabolites or biologically-relevant molecular species, producing spectra of excellent quality with little overlap. We also employed robust SVM classifiers to characterize brain tumor biopsies with high sensitivity, specificity, and accuracy. One principal finding is that our linear SVM with MRMR feature selection results in robust selection of the reduced feature space, and provides a data-driven criterion for generalization of the feature selection as the training set changes (e.g., increases in size as more data are added) leading to excellent classification performance, comparable to what is obtained when using the full-feature space. These findings enhance our knowledge from prior studies [8-12], since they suggest that the inclusion of more metabolites increases the performance of a given classification system, especially its sensitivity and accuracy. In vivo MRS at higher field strengths with 2D methods that allow the detection at least the same 16 metabolites that we reliably quantified, should enable clinicians to characterize and diagnose even inoperable brain tumors with high accuracy. This should allow appropriate therapy selection and the non-invasive monitoring of such therapies in vivo, thereby avoiding serial biopsies. Indeed, using molecular information to guide brain tumor therapy has been suggested [13].

References